drugset / Trial / NCT04798326
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW032 and Xgeva® in healthy adults.
Timeline
- Start
- 2019-06-25
- Primary completion
- 2020-01-10
- Completion
- 2020-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | MW032 | Monoclonal antibody | 120 mg | Subcutaneous |